Drug Database
AD

adjuvants (ImmuMax / ImmuMax SR / adjuvants, Repros)

✓ Approved

Repros Therapeutics Inc. · 小分子 · 小分子

什么是 adjuvants?

adjuvants 是一种小分子,由Repros Therapeutics Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名ImmuMax, ImmuMax SR, adjuvants, Repros
公司Repros Therapeutics Inc.
药物类别小分子
给药途径Unknown
状态Approved

治疗适应症

adjuvants 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedVeterinary immunology and immunopathology2026-11-18

Enhancement of immune responses to newcastle disease and avian influenza vaccines by GM-CSF and FliC as biological adjuvants in SPF chickens.

Sun Wenying W, Wang Jingming J, Zhang Lin L, Xue Zhiqiang Z et al.

Avian Influenza (AI) and Newcastle Disease (ND) are two acute, highly contagious infectious diseases that frequently affect poultry production and result in severe economic damage. Although vaccination is the primary means of controlling AI and ND outbreaks, currently available vaccines typically suffer from weak immunogenicity and a delayed onset of protective immunity. Therefore, it is crucial to identify suitable adjuvants to enhance the effectiveness of vaccines. In this study, Hemagglutinin (HA), granulocyte-macrophage colony stimulating factor (GM-CSF), and flagellin (FliC) were expressed in E. coli prokaryotic expression systems, SPF chickens were inoculated with HA vaccine and two types of ND-AI bivalent vaccines with chicken GM-CSF (chGM-CSF) and FliC as adjuvants separately or combined. The impact of these adjuvants on immune responses was evaluated through multiple indicators: serum antibody levels against NDV and AIV; percentages of CD4⁺ T lymphocytes, CD8⁺ T lymphocytes, and B cells among leukocytes; serum concentrations of the cytokines IL‑4, IL‑1β, IFN‑γ, and GM‑CSF; and the mRNA expression of IL‑4, IL‑6, IL‑1β, TNF‑α, IFN‑γ, and GM‑CSF in both leukocytes and spleen tissue. The findings demonstrated that vaccines formulated with combined adjuvants induced stronger humoral, cellular, and inflammatory immune responses, and these responses lasted longer than those elicited by vaccines containing a single adjuvant or no adjuvant. At necropsy, no obvious gross lesions were observed in the bursa, spleen, thymus, or lungs of vaccinated chickens, consistent with hematoxylin and eosin (HE) staining, which revealed no inflammatory infiltration, tissue necrosis, or structural destruction in these tissues, indicating favorable tissue safety of the tested vaccine formulations. Notably, this study was performed in SPF chickens under laboratory conditions; therefore, further validation in field settings, including challenge testing and gross lesion assessment, is warranted. Collectively, this research lays a foundation for the future use of biological adjuvants in vaccine development.

PMID 43050717
阅读全文 →
PubMedJournal of anaesthesiology, clinical pharmacology2026-11-18

Ultrasound-guided costotransverse block with systemic adjuvants for complete opioid-free breast cancer surgery: A randomized controlled trial.

Banish T M TM, Sethi Priyanka P, Mathur Rhythm R, Dang Deepanshu D et al.

Modified radical mastectomy (MRM) is associated with significant postoperative pain requiring opioid analgesia. Opioids carry undesirable effects including nausea, sedation, respiratory depression, opioid-induced hyperalgesia, and potential immune suppression that may impact oncological outcomes. This randomized controlled trial assessed the effectiveness of opioid-free anesthesia using ultrasound-guided costotransverse block (CTB) with multimodal systemic adjuvants on analgesic outcomes and recovery quality in breast cancer surgery. This prospective, open-label, randomized controlled trial was conducted at tertiary care center with institutional ethics approval. Sixty-six female patients (American society of anesthesiologist physical staus grade(ASA) I-III) undergoing MRM were randomly allocated (1:1) to opioid-based anesthesia (Group A, n = 33) or opioid-free anesthesia with T4-level CTB using 0.5% ropivacaine (15 mL) plus dexmedetomidine (0.5 µg/kg/h), lidocaine (1.5 mg/kg bolus, 2 mg/kg/h infusion), and magnesium sulfate (30 mg/kg over 20 minutes) (Group B, n = 33). The primary outcome was 24-h fentanyl consumption. Secondary outcomes included intraoperative opioid requirements, time to first rescue analgesia, pain scores, quality of recovery-15 at 48 h, and complications. Complete elimination of perioperative opioid requirements was achieved in Group B. Intraoperative fentanyl consumption in Group B was 0 µg vs Group A 150 (132.5-150) µg (P < 0.001). Postoperative 24-h fentanyl consumption was Group B 0 µg vs Group A 60 (40-60) µg (P < 0.001). None of the Group B patients (0%) required rescue analgesia in comparison to Group A patients (100%), who required rescue analgesia at a median of 3 (3-4) h (P < 0.001). Pain scores were significantly lower in Group B at all time points during rest and movement (P < 0.001). Quality of recovery scores were superior in Group B: 128 (122-130) vs 88 (84-90) (P < 0.001). Postoperative nausea and vomiting incidence was reduced: 6% vs 24% (P = 0.086, not statistically significant). No block-related complications occurred. Ultrasound-guided CTB with multimodal systemic adjuvants provided complete elimination of perioperative opioid requirements while achieving superior pain control, enhanced recovery quality, and excellent safety in MRM. This opioid-free approach offers a clinically viable alternative to conventional opioid-based techniques. This approach can be a safe inclusion in enhanced recovery protocols for breast cancer surgery.

PMID 43048737
阅读全文 →
PubMedBiomeditsinskaia khimiia2026-11-18

SPR-based analysis of the interaction of actinoporin from the sea anemone Heteractis crispa with lipid bilayers.

Gnedenko O V OV, Zelepuga E A EA, Monastyrnaya M M MM, Kaluzhskiy L A LA et al.

Sea anemone actinoporins are the proteins belonging to the family of α-pore-forming toxins. They attract considerable interest as potential components for immunotoxins used in cancer therapy, adjuvants in the development of vaccines to enhance the immune response, and for the creation of biosensor systems based on protein nanopores. The only identified cellular target for actinoporins is the cytoplasmic membrane of eukaryotic cells, containing sphingomyelin (SM). In this study, using surface plasmon resonance (SPR) technology, we have investigated the interaction between the actinoporin RTX-A from the sea anemone Heteractis crispa and lipid bilayer membranes (BLMs), both with and without SM. We have found that RTX-A interacts with BLMs regardless of the presence of SM. In the case of SM-containing BLMs, the sensorgrams reflect the sum of two independent interactions: the analyte (RTX-A) binding to two distinct ligands, phosphatidylcholine (PC) and SM, with Kd values of approximately 10-8 M and 4.6×10-9 M, respectively. The presence of SM in the BLMs did not affect the affinity of the interaction between RTX-A and PC.

PMID 43046918
阅读全文 →
PubMedNeurology2026-11-18

Pearls & Oy-sters: Reversible Rapidly Progressive Dementia Associated With ASIA Syndrome Secondary to Silicone Implants.

Guevara Carlos C, Morales Diego D, Torres Alejandra A, Naves Rodrigo R

A 33-year-old woman with a medical history of polycystic ovary syndrome on combined oral contraceptive pills, insulin resistance, and bilateral silicone breast implants (SBIs) placed 10 years prior presented with a 2-month history of intermittent myoclonic jerks involving the head, trunk, and lower limbs; polyarthralgia; and cognitive and functional decline (compared with being previously independent in her activities of daily living). Family history was significant for epilepsy in her mother and 2 brothers. Neurologic examination revealed disorientation, significantly impaired short-term recall, visuospatial memory impairment, and a limited attention span. Her speech was characterized by frequent paraphasic errors and anomia; she also exhibited mild gait ataxia. Diagnostic studies ruled out common autoimmune diseases. Brain MRI and electroencephalography revealed no abnormalities, and CSF analysis was normal. Genetic testing for inherited prion disease and Huntington disease was negative, and serum and urinary copper levels were unremarkable. As part of a paraneoplastic workup, breast MRI revealed intracapsular rupture of both SBIs. The implants were surgically removed with complete capsulectomy. The patient's symptoms resolved completely by the seventh postoperative day. At the 6-month follow-up, she remained asymptomatic and had returned to her baseline functional status. Given the temporal association between implant rupture, explantation, and symptom resolution, the presentation was considered most consistent with a case of reversible rapidly progressive dementia secondary to the autoimmune/inflammatory syndrome induced by adjuvants.

PMID 43050643
阅读全文 →
PubMedJournal of anaesthesiology, clinical pharmacology2026-11-18

Utility of programmed intermittent bolus infusion modality in peripheral nerve catheters for postoperative pain management - A systematic review and meta-analysis.

Karuppusami Reka R, Sharma Shalu S, Cherian Noble E NE, Ravikumar Jennifer S JS et al.

Continuous peripheral nerve block catheters deliver prolonged anesthesia or analgesia during the perioperative period and have evolved into established practices. Recent advancements in regional anesthesia aim to improve patient outcomes by reducing morbidity. Despite the use of adjuvants, single injection pain management typically lasts only 16 to 24 hours. Alternatively, continuous infusion (CI) pumps may increase local anesthetic doses, raising the risk of toxicity and opioid use. The newly evaluated programmed intermittent bolus (PIB) pumps show promise for peripheral nerve blocks, yet a Cochrane Library search indicates a gap in research, with only handful of registered trials on this topic. This highlights the need for further investigation and subgroup analyses to strengthen evidence for this modality in pain management. In accordance with the PROSPERO registry protocol for this review, we conducted a literature search to evaluate the safety and effectiveness of the PIB pumps in peripheral nerves blocks for postoperative pain management. Our primary outcomes included pain scores, consumption of local anesthetics, morphine, and rescue analgesics, as well as any encountered side effects. There were 25 published randomized controlled trials, meeting the inclusion criteria, comprising 1572 patients, directly comparing PIB and CI, and explaining all the comparatives with rare complications. Despite the ever growing quest to find the ideal postoperative pain management method, there is limited literature and it is insufficient to guide clinical practice. Our study underscores the utility of PIB. PIB proves a better analgesic mode than CI.

PMID 43048702
阅读全文 →
PubMedAnnals of palliative medicine2026-11-18

Pain in oncological diseases: a narrative review.

Semedo Valéria V, Dourado Marília M, Pedro Maria Ivete MI, Martins Ivis I et al.

Cancer pain is a frequent, multifactorial symptom that affects almost half of patients with cancer and more than half of those with advanced disease, and approximately one-third remain undertreated. Despite the availability of international guidelines, important gaps persist between evidence and practice. This narrative review aims to synthesize current evidence on the mechanisms, epidemiology and pharmacological, non-pharmacological and disease-directed management of cancer pain, to identify gaps in knowledge and practice, and to discuss practical implications for assessment and multidisciplinary care. PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Library and SciELO/LILACS were searched for articles published in English, Portuguese or Spanish between January 2000 and July 2026, complemented by guideline repositories and hand-searching of reference lists. Clinical practice guidelines, systematic reviews, meta-analyses, randomized controlled trials and relevant observational studies in adults with cancer were prioritized. Cancer pain arises from nociceptive, neuropathic, mixed and breakthrough mechanisms and requires individualized, mechanism-based treatment. Strong opioids remain the mainstay for moderate-to-severe pain, with no single opioid consistently superior; opioid rotation, cautious equianalgesic conversion and opioid stewardship, including medication review and deprescribing in frail patients, improve safety. Adjuvants have mechanism-specific roles, with the strongest evidence for duloxetine in chemotherapy-induced peripheral neuropathy. Radiotherapy is highly effective for painful bone metastases, and interventional and surgical procedures benefit selected patients with refractory or structural pain. Non-pharmacological interventions provide small-to-moderate benefits of variable certainty, which are most consistent when matched to specific patient profiles. Patient-, professional- and system-level barriers limit implementation and can be addressed through routine screening, standardized prescriptions, predefined referral pathways, interprofessional education, audit and feedback, and early integration of palliative care. Optimal cancer pain care is multimodal, interdisciplinary and person-centred. Future research should prioritize comparative trials, standardized dosing of non-pharmacological interventions, identification of responder subgroups, implementation studies and validation of precision tools such as pharmacogenomics, electronic patient-reported outcomes and artificial intelligence-based decision support.

PMID 43051203
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adjuvants